The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.

In February and September of each year, the World Health Organization (WHO) announces flu vaccine formulations for the northern and southern hemispheres. To support vaccine research and development, The Native Antigen Company has developed Haemagglutinin and Neuraminidase antigens for the WHO-recommended, egg-based and recombinant vaccine strains. Available in bulk quantities, the latest range of antigens can be used in a range of applications, including immunoassay development and as immunogens, and includes reagents for both influenza A and B.

The Native Antigen Company’s influenza antigens were developed using the Company’s proprietary mammalian expression system, VirtueE. The antigen exhibits full glycosylation and folding to ensure that antibodies raised against it are highly specific. The Haemagglutinin antigens feature C-terminal T4 foldon domains, stabilizing them in their trimeric conformation to present more native-like conformational epitopes.

Each year, we are proud to be able to support vaccine and diagnostic manufacturers by updating our range of influenza reagents in line with WHO’s guidance. Our customers now have access to the very latest, high-quality antigens for vaccine reformulation, to ensure the public continues to stay safe during the 2023 flu season.”

Ish Jalal, Commercial Director, The Native Antigen Company

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    The Native Antigen Company. (2022, November 21). The Native Antigen Company introduces new range of influenza antigens. AZoLifeSciences. Retrieved on December 08, 2022 from https://www.azolifesciences.com/news/20221121/The-Native-Antigen-Company-introduces-new-range-of-influenza-antigens.aspx.

  • MLA

    The Native Antigen Company. "The Native Antigen Company introduces new range of influenza antigens". AZoLifeSciences. 08 December 2022. <https://www.azolifesciences.com/news/20221121/The-Native-Antigen-Company-introduces-new-range-of-influenza-antigens.aspx>.

  • Chicago

    The Native Antigen Company. "The Native Antigen Company introduces new range of influenza antigens". AZoLifeSciences. https://www.azolifesciences.com/news/20221121/The-Native-Antigen-Company-introduces-new-range-of-influenza-antigens.aspx. (accessed December 08, 2022).

  • Harvard

    The Native Antigen Company. 2022. The Native Antigen Company introduces new range of influenza antigens. AZoLifeSciences, viewed 08 December 2022, https://www.azolifesciences.com/news/20221121/The-Native-Antigen-Company-introduces-new-range-of-influenza-antigens.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post